Premium
Sodium valproate in the management of painful neuropathy in type 2 diabetes – a randomized placebo controlled study
Author(s) -
Kochar D. K.,
Jain N.,
Agarwal R. P.,
Srivastava T.,
Agarwal P.,
Gupta S.
Publication year - 2002
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2002.01229.x
Subject(s) - medicine , placebo , anesthesia , diabetic neuropathy , randomized controlled trial , mcgill pain questionnaire , diabetes mellitus , aspartate transaminase , endocrinology , biochemistry , chemistry , alkaline phosphatase , alternative medicine , enzyme , pathology , visual analogue scale
Kochar DK, Jain N, Agrawal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes – a randomized placebo controlled study. Acta Neurol Scand 2002: 106: 248–252. © Blackwell Munksgaard 2002. Objective – To study the effectiveness and safety aspects of sodium valproate in the management of painful neuropathy in patients of type 2 diabetes mellitus. Material and methods – A randomized double‐blind placebo controlled trial of sodium valproate was done in type 2 diabetic patients to assess its efficacy and safety in the management of painful neuropathy. We screened 60 patients but eight patients could not complete the study; hence, the present study was done on 52 patients. Each patient was assessed by clinical examination, pain score by short form of the McGill pain questionnaire (SF‐MPQ) and electrophysiological examination, which included motor and sensory nerve conduction velocity, amplitude and H‐reflex initially and at the end of 1 month of treatment. Results – Significant improvement was noticed in the pain score of patients receiving sodium valproate in comparison to patients receiving placebo at the end of 1 month ( P < 0.05). The changes in electrophysiological data were not significant. The drug was well tolerated by all patients except one who developed a raised aspartate transaminase (AST)/alanine transaminase (ALT) level after 15 days of treatment. Conclusion – Sodium valproate is a well‐tolerated drug and provides significant subjective improvement in painful diabetic neuropathy. These data provide a basis for future trials of longer duration in a larger group of patients.